Pirtobrutinib
Jaypirca · BTKi (non-covalent) · BTK
First non-covalent (reversible) BTK inhibitor. Active against C481S BTK mutations that cause resistance to covalent BTKis.
Relapsed/refractory MCL after at least two prior therapies including a covalent BTK inhibitor
Jonathon Cohen
Professor, Co-Director of Lymphoma Program · Emory University / Winship Cancer Institute
Krish Patel
Director of Lymphoma Research · Sarah Cannon Research Institute
Michael Wang
Professor, Department of Lymphoma and Myeloma; Director, MCL Program of Excellence · MD Anderson Cancer Center
Preetesh Jain
Assistant Professor, Department of Lymphoma and Myeloma · MD Anderson Cancer Center
Dissecting Pirtobrutinib Resistance in Mantle Cell Lymphoma Through Single-Cell Multi-Omics.
American journal of hematology · Apr 2026
Evolving therapeutic strategies in mantle cell lymphoma: advancements and future directions.
Leukemia · Apr 2026
Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders.
Pharmacological research · Apr 2026
First Fluorescence Method for Native Quantification of Pirtobrutinib Used for Treatment of Cancer in its Market Form and Biological Fluids; Application of Greenness.
Journal of fluorescence · Feb 2026
Pirtobrutinib in relapsed or refractory mantle cell lymphoma: outcomes from the compassionate use program in Italy.
Leukemia & lymphoma · Jan 2026
Cutaneous Adverse Effects in Patients Treated with BTK Inhibitors.
Cancers · Jan 2026
BTK Inhibition in Hematology: From CLL/SLL to Emerging Applications Across B-Cell and Immune Disorders.
Biomolecules · Jan 2026
A matching-adjusted indirect comparison of survival outcomes with pirtobrutinib (BRUIN) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma previously treated with a covalent Bruton tyrosine kinase inhibitor.
British journal of haematology · Jan 2026
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis.
Current medical research and opinion · Dec 2025
Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options?
European journal of haematology · Dec 2025
TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma.
Blood · Nov 2025
Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis.
Blood advances · Nov 2025
Pirtobrutinib in Chinese patients with relapsed or refractory B-cell malignancies: A single-arm, open-label, phase 2, multicenter trial.
International journal of cancer · Jun 2025
High-Performance Liquid Chromatography-Ultraviolet Assay for the Determination of Pirtobrutinib Levels in a Patient With Mantle Cell Lymphoma.
Biomedical chromatography : BMC · May 2025
From development to clinical success: the journey of established and next-generation BTK inhibitors.
Investigational new drugs · Apr 2025
Development of a novel UHPLC-MS/MS method for quantitative analysis of pirtobrutinib in rat plasma: application to pharmacokinetic study.
BMC chemistry · Feb 2025
Ganciclovir-resistant CMV encephalitis in a mantle cell lymphoma patient on pirtobrutinib: Case report.
IDCases · Jan 2025
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.
Haematologica · Jan 2025
Evaluating pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma.
Expert review of hematology · Oct 2024
Pirtobrutinib: A New and Distinctive Treatment Option for B-Cell Malignancies.
The Annals of pharmacotherapy · Oct 2024